The Precision Revolution in Hematologic Malignancies: A Decade of Transformative Immunotherapies and Targeted Agents.

1. Introduction

Hematologic malignancies encompass a diverse spectrum of cancers affecting blood-forming tissues, including leukemias, lymphomas, myelomas, and myelodysplastic syndromes, collectively accounting for approximately 10% of all new cancer diagnoses globally [ 1 ].

The past decade has witnessed an unprecedented transformation in the therapeutic landscape of these diseases, driven by advances in our understanding of disease biology, the development of targeted therapies, and the emergence of novel immunotherapeutic approaches [ 2 ]. Traditional treatment paradigms, which relied heavily on cytotoxic chemotherapy and radiation therapy, have increasingly given way to precision medicine approaches that target specific molecular alterations and harness the immune system’s capacity to recognize and eliminate malignant cells [ 3 ]. The regulatory landscape has adapted accordingly, with the FDA approving 66 new drugs for hematologic malignancies between 2019 and 2024, with 53% of these approvals based on early-phase clinical trial data [ 4 ].

This therapeutic renaissance has been characterized by several paradigm-shifting developments. CAR-T cell therapy has evolved from an experimental treatment to a standard-of-care option, with six CAR-T products now FDA-approved for various hematologic indications [ 5 ]. BTK inhibitors (BTK = Bruton’s tyrosine kinase) have revolutionized the treatment of B-cell malignancies, particularly chronic lymphocytic leukemia (CLL) and mantle cell lymphoma, with newer-generation agents offering improved safety profiles [ 6 ]. The BCL-2 inhibitor genetical has demonstrated remarkable synergy with hypomethylating agents in acute myeloid leukemia (AML), leading to its adoption as first-line therapy for older patients [ 7 ].

This review provides a comprehensive analysis of the most significant therapeutic advances in hematologic malignancies, examining the clinical evidence supporting these innovations, their integration into current treatment algorithms, and the challenges that remain. We will explore recent developments in immunotherapy, targeted therapy, and combination strategies while discussing emerging resistance mechanisms and future therapeutic directions. Unlike recent reviews focusing on single modalities or specific diseases, this work provides a cross-disease synthesis of immunotherapy and targeted therapy advances, integrates regulatory and economic perspectives, and highlights future directions in trial design and biomarker development.

2. Recent Developments in Hematologic Malignancy Therapeutics

2.1. CAR-T Cell Therapy: Expanding Applications and Enhanced Efficacy

Chimeric antigen receptor T-cell therapy represents one of the most transformative advances in cancer treatment, with particular impact in hematologic malignancies [ 8 ]. The field has progressed rapidly from initial proof-of-concept studies to widespread clinical implementation, with ongoing research focused on expanding target antigens, improving manufacturing processes, and reducing toxicities.

Recent clinical trials have demonstrated the efficacy of CAR-T therapy in earlier treatment lines, most notably with the FDA approval of axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) for second-line treatment of large B-cell lymphoma [ 9 ]. The landmark TRANSFORM study showed that liso-cel significantly improved event-free survival compared to standard salvage chemotherapy followed by autologous stem cell transplant, with a median event-free survival not reached versus 2.4 months (HR 0.349, 95% CI 0.254–0.478, p < 0.0001) [ 9 ].

Manufacturing innovations have focused on improving CAR-T cell expansion, persistence, and functionality [ 10 ]. CRISPR-based gene editing approaches are being explored to enhance CAR-T cell performance by deleting immune checkpoint receptors [ 11 ]. The development of “off-the-shelf” allogeneic CAR-T products aims to address manufacturing delays and expand patient access, though challenges related to graft-versus-host disease and immune rejection remain to be fully resolved.

Toxicity management has evolved significantly, with improved understanding of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) [ 8 ]. Real-world data demonstrate that CRS occurs in approximately 40–50% of patients receiving currently approved CAR-T products, with grade 3–4 CRS in less than 10% of cases [ 12 ]. Prophylactic strategies, including tocilizumab administration and corticosteroids, have shown promise in reducing severe toxicity without compromising efficacy [ 13 ].

2.2. BTK Inhibitors: Second-Generation Agents and Beyond

The BTK inhibitor landscape has evolved considerably since the initial approval of ibrutinib, with second-generation agents offering improved selectivity and reduced off-target effects [ 14 ]. Acalabrutinib and zanubrutinib have demonstrated superior safety profiles compared to ibrutinib in head-to-head clinical trials, with significantly reduced rates of atrial fibrillation, hypertension, and bleeding complications.

The ELEVATE-RR trial demonstrated that acalabrutinib was associated with significantly fewer cardiovascular adverse events compared to ibrutinib in patients with CLL, with atrial fibrillation occurring in 9.4% versus 16.0% of patients, respectively ( p = 0.02) [ 6 ]. Similarly, the ALPINE study showed that zanubrutinib had superior progression-free survival and fewer side effects compared to ibrutinib [ 15 ].

Resistance to BTK inhibitors has emerged as a significant clinical challenge, primarily mediated by mutations at the C481 binding site of BTK or downstream signaling components such as PLCγ2 [ 16 ]. These observations have driven the development of non-covalent BTK inhibitors, including pirtobrutinib, which maintains activity against C481S-mutant BTK [ 17 ]. Clinical trials of pirtobrutinib have shown overall response rates of approximately 70% in patients with prior BTK inhibitor exposure, regardless of resistance mechanism [ 18 ].

Novel approaches to BTK targeting include BTK degraders, which promote the degradation of the entire BTK protein rather than simply inhibiting its kinase activity. These agents demonstrate activity against both wild-type and mutant forms of BTK and represent a promising strategy for overcoming resistance [ 19 ].

2.3. Venetoclax and Combination Strategies in AML

The BCL-2 inhibitor venetoclax has fundamentally altered the treatment landscape for AML, particularly in older adults who are ineligible for intensive chemotherapy [ 7 ].

Triplet combinations incorporating venetoclax have shown particular promise in molecularly defined subgroups of AML [ 20 ]. The addition of gilteritinib to venetoclax and azacitidine in FLT3-mutated AML achieved a complete remission rate of 90% in newly diagnosed patients, with 65% of evaluable patients achieving FLT3-ITD measurable residual disease negativity. These results support the concept of mutation-directed therapy selection and the potential for cure in historically high-risk subgroups [ 20 ].

IDH inhibitor combinations with venetoclax have also demonstrated encouraging results [ 21 ]. Network meta-analysis suggests that venetoclax plus azacitidine may provide superior overall survival compared to IDH inhibitor combinations in IDH-mutated AML, though direct comparative studies are needed to confirm these findings [ 22 ]. The landmark VIALE-A trial established venetoclax plus azacitidine as a new standard for unfit AML, demonstrating superior overall survival versus azacitidine alone (14.7 vs. 9.6 months; HR 0.66). This regimen has since been integrated into global guidelines and inspired triplet combinations in molecularly defined subgroups.

2.4. Bispecific Antibodies in Multiple Myeloma

Bispecific antibodies have emerged as a transformative therapy for multiple myeloma, with three agents now FDA-approved for heavily pretreated patients [ 23 ]. Teclistamab, elranatamab, and talquetamab target BCMA or GPRC5D, redirecting T-cells to myeloma cells and achieving remarkable response rates in triple-class-exposed patients.

Clinical trials have demonstrated overall response rates of 60–74% with these agents, with complete response rates ranging from 25 to 50% [ 24 ]. The MajesTEC-1 study of teclistamab showed an overall response rate of 63% in heavily pretreated patients, with a median progression-free survival of 11.3 months. Real-world evidence has largely confirmed these efficacy results [ 25 ]. while providing insights into optimal patient selection and toxicity management [ 26 ]. Resistance mechanisms to bispecific antibodies are becoming better understood, with antigenic changes being a primary mechanism of escape [ 27 ]. T-cell characteristics, including the presence of regulatory T-cells and expression of exhaustion markers, significantly impact response to bispecific antibody therapy [ 28 ]. Strategies to overcome resistance include combination with immunomodulatory agents, immune checkpoint inhibitors [ 29 ].

2.5. Menin Inhibitors: Targeting Transcriptional Dependencies

Menin inhibitors represent a novel class of targeted therapies for acute leukemias driven by KMT2A rearrangements or NPM1 mutations [ 30 ]. These agents work by disrupting the interaction between menin and the KMT2A protein complex, leading to downregulation of HOXA9 and MEIS1 transcription factors that are essential for leukemic cell survival.

Revumenib became the first FDA-approved menin inhibitor based on results from the AUGMENT-101 study, which demonstrated an overall response rate of 68% in heavily pretreated KMT2A-rearranged acute leukemia patients [ 31 ]. The median duration of response was 9.1 months, with differentiation syndrome being the most significant toxicity concern, occurring in approximately 16% of patients [ 31 ].

Ziftomenib, another menin inhibitor in clinical development, has shown similar efficacy [ 32 ]. Combination strategies with menin inhibitors are being actively investigated, including combinations with DOT1L inhibitors, which target a complementary chromatin-modifying enzyme in the same pathway [ 33 ].

2.6. Therapeutic Advances by Disease Category

2.6.1. Acute Myeloid Leukemia

AML has experienced a therapeutic renaissance with the approval of multiple targeted agents over the past five years [ 34 ]. Beyond venetoclax combinations, FLT3 inhibitors have established a clear benefit in FLT3-mutated disease [ 35 ].

Midostaurin in combination with standard chemotherapy demonstrated improved overall survival in newly diagnosed FLT3-mutated AML [ 36 ], while gilteritinib showed superiority over salvage chemotherapy in relapsed/refractory disease [ 37 ].

IDH inhibitors have provided targeted therapy options for the approximately 20% of AML patients harboring IDH1 or IDH2 mutations [ 38 ]. Ivosidenib and enasidenib have demonstrated efficacy in relapsed/refractory disease, with ongoing studies evaluating their integration into frontline therapy. The combination of IDH inhibitors with intensive chemotherapy has shown promising preliminary results, with high rates of morphologic remission and IDH mutation clearance [ 39 ].

Emerging targets in AML include MCL-1, which represents a potential mechanism of venetoclax resistance. MCL-1 inhibitors are in early-phase clinical development and may provide synergistic activity when combined with venetoclax [ 40 , 41 ]. Collectively, these advances have transformed AML into a molecularly stratified disease, where targeted agents now offer meaningful survival benefits across genetic subsets.

The principles of precision oncology have been validated in pediatric malignancies through landmark biomarker-driven trials. Initiatives such as the INFORM (Individualized Therapy For Relapsed Malignancies in Childhood) registry and MAPPYACTS have demonstrated the feasibility of comprehensive molecular profiling (including whole-genome/exome and RNA sequencing) to identify actionable alterations and guide targeted therapy in children with relapsed/refractory cancers, including AML [ 42 , 43 ]. These studies have successfully matched a significant proportion of pediatric patients to targeted agents (e.g., FLT3 or IDH inhibitors, MEK inhibitors) based on molecular findings, leading to clinically meaningful responses. This paradigm reinforces the universal applicability of biomarker-driven treatment strategies and highlights the critical need to expand access to molecular testing and novel therapies across all age groups.

2.6.2. Chronic Lymphocytic Leukemia

CLL treatment has been revolutionized by the availability of targeted therapies that provide superior efficacy compared to traditional chemoimmunotherapy while offering improved tolerability profiles [ 6 ]. The combination of BTK inhibitors with venetoclax has emerged as a highly active regimen capable of achieving deep remissions, including undetectable measurable residual disease in a significant proportion of patients [ 44 ].

The CLL14 study demonstrated that venetoclax plus obinutuzumab achieved superior progression-free survival compared to chlorambucil plus obinutuzumab in previously untreated CLL patients, with the additional benefit of fixed-duration therapy [ 45 ]. The CAPTIVATE study showed that ibrutinib plus venetoclax achieved undetectable measurable residual disease in 77% (peripheral blood) and 60% (bone marrow) of the patients after 12 cycles of combination therapy.

For patients with high-risk features such as del(17p) or TP53 mutations, both BTK inhibitors and venetoclax-based regimens have demonstrated superior efficacy compared to chemotherapy. These patients, who previously had extremely poor outcomes with conventional therapy, can now achieve durable remissions with targeted approaches [ 46 ]. Thus, CLL management has evolved toward chemotherapy-free, fixed-duration regimens capable of achieving deep molecular remissions, even in high-risk disease.

The success of precision medicine in CLL is part of a broader trend in hematologic oncology, further exemplified by pediatric precision medicine programs. Studies like iTHER (Innovative Therapies for Children with Cancer) and others have shown that comprehensive molecular characterization can reveal targetable pathways in relapsed pediatric leukemias and lymphomas, leading to the compassionate use of targeted agents (e.g., BTK inhibitors in certain contexts) [ 47 ]. These efforts underscore the translational potential of molecular diagnostics and the importance of extending biomarker-driven trial designs to encompass both adult and pediatric populations to accelerate therapeutic discovery.

2.6.3. B-Cell Lymphomas

The historical introduction of rituximab, a chimeric anti-CD20 monoclonal antibody, in the late 1990s marked the first successful application of therapeutic monoclonal antibodies in oncology and revolutionized the treatment of B-cell non-Hodgkin lymphomas (NHL) [ 48 ]. Its addition to CHOP chemotherapy (R-CHOP) significantly improved survival in diffuse large B-cell lymphoma (DLBCL) and became the global standard of care, establishing the proof-of-concept for antibody-based immunotherapy [ 49 ]. This milestone paved the way for subsequent generations of antibody-based therapies, including antibody-drug conjugates (e.g., brentuximab vedotin, polatuzumab vedotin) and bispecific antibodies, illustrating the iterative and cumulative nature of innovation in lymphoma therapeutics. The therapeutic landscape for aggressive B-cell lymphomas has been transformed by the introduction of CAR-T therapy and novel agents targeting specific molecular subtypes. The ability to move CAR-T therapy to earlier treatment lines has the potential to cure patients who would otherwise face poor outcomes with standard salvage approaches [ 50 ]. Figure 1 outlines the mechanisms of CAR T-cell therapy and bispecific antibodies, emphasizing their role in redirecting immune responses against malignant cells.

Antibody-drug conjugates have also shown significant promise in lymphoma treatment. Brentuximab vedotin has demonstrated activity in CD30-expressing lymphomas [ 51 ] while polatuzumab vedotin combined with rituximab and bendamustine improved overall survival in relapsed/refractory diffuse large B-cell lymphoma [ 52 ].

Precision medicine approaches in lymphoma increasingly rely on molecular subtyping to guide therapy selection. The identification of specific genetic alterations, such as MYC rearrangements, BCL2/BCL6 translocations, and mutations in genes such as TP53, helps inform prognosis and treatment decisions. Novel agents targeting specific pathways, including PI3K inhibitors and BCL-2 inhibitors, provide targeted options based on molecular characteristics [ 53 ]. Together, CAR T-cell therapy, antibody-drug conjugates, and molecular subtyping are redefining lymphoma care, moving toward personalized and potentially curative strategies.

2.6.4. Multiple Myeloma

Multiple myeloma has benefited from an extensive array of new therapeutic options, including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and, more recently, bispecific antibodies and CAR-T therapy. The sequential introduction of these agents has led to a substantial improvement in overall survival, with many patients now living for decades with their disease [ 54 ].

BCMA-directed therapies have shown particular promise, with both CAR-T cell therapy (idecabtagene vicleucel and ciltacabtagene autoleucel) and bispecific antibodies demonstrating high response rates in heavily pretreated patients. The challenge moving forward will be optimal sequencing of these therapies and development of strategies to overcome resistance mechanisms [ 55 ].

Novel targets beyond BCMA are being actively investigated, including GPRC5D and FcRH5 [ 56 ]. These alternative targets may provide options for patients with BCMA-negative disease or those who have developed resistance to BCMA-directed therapies. Early phase studies of GPRC5D-targeted bispecific antibodies have shown encouraging results, with response rates comparable to BCMA-targeted agents [ 57 ]. Figure 2 summarizes the evolving treatment paradigm, and Figure 3 is an infographic for targeted therapies. Table 1 summarizes the various novel therapies in these malignancies. The rapid succession of novel immunotherapies has markedly improved outcomes in myeloma, though optimal sequencing remains a key clinical challenge.

2.6.5. Advances in Pediatric Hematologic Cancers

While this review focuses primarily on adult malignancies, pediatric hematologic cancers have also seen transformative advances, exemplified by the incorporation of blinatumomab and nelarabine in ALL regimens (e.g., ALLTOGETHER study) and the historical milestone of rituximab as the first therapeutic monoclonal antibody in lymphoma. Pediatric precision oncology initiatives such as INFORM, iTHER, and MAPPYact demonstrate the feasibility of molecular profiling to guide targeted therapy in children, though access barriers remain significant.

2.6.6. Acute Lymphoblastic Leukemia (ALL)

The treatment landscape for B-cell acute lymphoblastic leukemia (B-ALL) has been transformed by immunotherapy, particularly in high-risk and relapsed/refractory disease. Blinatumomab, a bispecific T-cell engager targeting CD19, demonstrated superior outcomes compared to chemotherapy in relapsed/refractory B-ALL, leading to its approval in both adult and pediatric populations [ 58 ]. More recently, inotuzumab ozogamicin, an antibody-drug conjugate targeting CD22, has shown significant efficacy with higher rates of complete remission and minimal residual disease negativity compared to standard therapy in relapsed/refractory ALL [ 59 ]. These agents have been integrated into front-line and salvage regimens, including pediatric protocols such as the ALLTOGETHER study, which evaluates novel combinations in a risk-adapted manner [ 60 ]. The success of these immunotherapies underscores the shift from intensive, toxic chemotherapy to targeted immune-based strategies across all age groups.

2.7. Mechanistic Insights and Resistance Mechanisms

Understanding Therapeutic Resistance

The emergence of resistance to targeted therapies represents a critical challenge in hematologic malignancy treatment [ 61 ]. Resistance mechanisms are diverse and often involve mutations in target proteins, activation of alternative signaling pathways, or changes in the tumor microenvironment.

BTK inhibitor resistance primarily occurs through mutations at the C481 binding site, which disrupt the covalent binding of first-generation inhibitors [ 62 ]. However, resistance to non-covalent BTK inhibitors involves different mutations, including those at residues L528, M437, and T474 [ 63 ]. Venetoclax resistance involves multiple mechanisms, including upregulation of alternative anti-apoptotic proteins such as MCL-1, mutations in BCL-2 itself, and alterations in mitochondrial metabolism [ 41 ].

These insights have informed combination strategies aimed at preventing or overcoming resistance, such as the combination of venetoclax with MCL-1 inhibitors or metabolic modulators [ 40 ].

CAR-T cell resistance mechanisms include antigen loss or downregulation, T-cell exhaustion, and immunosuppressive microenvironmental factors [ 64 ]. Strategies to overcome CAR-T resistance include the use of multi-target CAR constructs and combination with immune checkpoint inhibitors or other immunomodulatory agents [ 65 ].

2.8. Biomarkers for Therapy Selection

The identification of predictive biomarkers has become increasingly important for optimal therapy selection in hematologic malignancies [ 66 ].

Genomic profiling at diagnosis can identify actionable mutations and inform treatment decisions, while monitoring of measurable residual disease provides insights into treatment response and relapse risk [ 67 ].

Liquid biopsies, including circulating tumor DNA (ctDNA) analysis, are emerging as valuable tools for treatment monitoring and resistance detection. In lymphoma, ctDNA clearance has demonstrated strong prognostic value and may serve as an earlier indicator of treatment efficacy compared to traditional imaging-based assessments [ 68 ].

Flow cytometry-based minimal residual disease monitoring has established prognostic significance in multiple disease contexts, like AML. Patients achieving undetectable MRD have superior outcomes across multiple treatment approaches, supporting the use of MRD as both a prognostic marker and potential surrogate endpoint in clinical trials [ 69 ].

2.9. Challenges and Controversies

2.9.1. Treatment Sequencing and Combination Strategies

The abundance of active agents in hematologic malignancies has created new challenges related to optimal treatment sequencing and combination design. The question of when to use intensive versus targeted approaches, particularly in younger patients who may be candidates for either strategy, remains a subject of ongoing investigation [ 70 ].

In CLL, the choice between continuous BTK inhibitor therapy and fixed-duration venetoclax-based combinations involves considerations of treatment duration, long-term toxicity, and patient preference. Both approaches have demonstrated superior efficacy compared to chemoimmunotherapy, but direct comparative studies are needed to establish optimal sequencing [ 71 ].

2.9.2. Toxicity Management and Quality of Life

While targeted therapies often have more favorable toxicity profiles compared to traditional chemotherapy, they are associated with unique side effects that require specialized management. CAR-T therapy-associated CRS and ICANS require intensive monitoring and may necessitate ICU-level care [ 8 ].

Standardized grading systems and treatment algorithms have improved outcomes, but toxicity remains a significant concern. Long-term effects of novel therapies are still being characterized, as many of these agents have only been in clinical use for a few years [ 8 ].

Secondary malignancies have been reported with some CAR-T products, highlighting the importance of long-term surveillance [ 8 ]. Similarly, the cardiovascular effects of BTK inhibitors require ongoing monitoring, particularly in older patients with multiple comorbidities [ 72 ].

Quality of life considerations are increasingly important in treatment decision-making, particularly as overall survival improves and patients live longer with their diseases [ 73 ].

Patient-reported outcome measures have shown that many targeted therapies maintain or improve quality of life compared to chemotherapy [ 74 ].

2.10. Evolution of Immunotherapeutic Modalities

The immunotherapy landscape has evolved from early monoclonal antibodies (e.g., rituximab) to antibody-drug conjugates (e.g., brentuximab vedotin, inotuzumab ozogamicin), bispecific T-cell engagers, and cellular therapies. Each modality leverages distinct mechanisms—from direct antigen targeting and payload delivery to immune cell redirection—contributing to the layered and increasingly personalized approach now standard in hematologic malignancies.

2.11. Clinical Implications and Future Directions

Personalized Medicine and Precision Oncology

The future of hematologic malignancy treatment will increasingly rely on comprehensive molecular profiling to guide therapy selection [ 75 ]. Whole-genome sequencing, RNA sequencing, and functional drug screening platforms are being developed to provide personalized treatment recommendations based on individual tumor characteristics [ 76 ].

Artificial intelligence and machine learning approaches are being applied to integrate multiple data types, including genomic, transcriptomic, and clinical data, to predict treatment responses and optimize therapy selection. These approaches may help predict resistance mechanisms before they become clinically apparent [ 77 ].

The development of patient-derived models, including organoids and xenografts, provides opportunities for functional testing of treatment approaches and combination strategies. These models may be particularly valuable for rare disease subtypes where clinical trial enrollment is challenging [ 78 ].

3. Novel Targets and Therapeutic Approaches

Emerging therapeutic targets in hematologic malignancies include epigenetic modifiers, metabolic enzymes, and components of DNA damage response pathways [ 79 ].

MALT1 protease inhibitors have shown promise in preclinical models of B-cell malignancies and may provide an alternative to BTK inhibition or serve as combination partners [ 80 ].

Immune-based approaches beyond CAR-T therapy are being actively investigated, including bispecific T-cell engagers, natural killer cell therapies [ 81 , 82 ]. These approaches may provide alternatives for patients who are not candidates for CAR-T therapy or as combination partners to enhance efficacy [ 82 ].

Gene editing approaches, including CRISPR-Cas9, are being explored both as therapeutic interventions and as tools to enhance existing therapies. In situ gene editing of T-cells could potentially improve CAR-T therapy by enhancing persistence, reducing exhaustion, or incorporating multiple target specificities [ 83 , 84 , 85 ].

Global Access and Health Economics

The high cost of many novel therapies in hematologic malignancies raises important questions about global access and health economics. CAR-T therapies can cost several hundred thousand dollars per treatment course [ 86 ]. Strategies to improve access include the development of simplified manufacturing processes for cellular therapies [ 87 ], biosimilar versions of expensive biologics [ 88 ], and risk-sharing agreements between manufacturers and health systems [ 89 ].

International cooperation and technology transfer may help extend access to novel therapies in resource-limited settings [ 90 ]. Value-based pricing models that tie reimbursement to clinical outcomes may help align costs with patient benefit while incentivizing continued innovation. Outcome-based contracts and real-world evidence generation will likely play increasingly important roles in drug pricing and reimbursement decisions [ 89 ]. Figure 4 shows the median launch price in US dollars for these agents.

4. Future Research Directions

4.1. Combination Therapy Development

Future clinical trials will need to address fundamental questions about optimal combination strategies, including the selection of rational partners, appropriate dosing and scheduling, and patient selection criteria [ 34 ]. Adaptive trial designs may be particularly valuable for evaluating multiple combinations efficiently while minimizing patient exposure to ineffective regimens [ 91 ]. In vivo CAR-T manufacturing using lipid nanoparticles remains a promising but challenging frontier, requiring resolution of delivery efficiency and immunogenicity concerns.

Biomarker-driven combination selection represents a promising approach for improving therapeutic indices. The identification of predictive markers for combination benefit could help select patients most likely to benefit from specific multi-agent regimens while avoiding unnecessary toxicity in others [ 92 ]. Optimal sequencing of CAR T-cell therapy and bispecific antibodies—particularly in relapsed myeloma and lymphoma—warrants prospective comparative studies.

Early phase combination studies should incorporate comprehensive correlative analyses to understand mechanisms of synergy and resistance. These studies will be critical for identifying biomarkers of response and developing strategies to overcome resistance [ 93 ].

4.2. Emerging Technologies

Advances in manufacturing and delivery technologies may help reduce costs and improve access to cellular therapies [ 94 ]. In vivo CAR-T generation using lipid nanoparticles could potentially eliminate the need for complex ex vivo manufacturing processes [ 94 ]. Digital health technologies, including wearable devices and smartphone applications, may enhance the monitoring of patients receiving novel therapies and enable earlier detection of toxicities. These technologies could be particularly valuable for managing patients receiving CAR-T therapy or other treatments associated with multiple side effects [ 95 ]. Advances in imaging and liquid biopsy technologies will likely provide more sensitive methods for treatment monitoring and response assessment [ 96 ]. Emerging MRD technologies, including high-sensitivity flow cytometry, next-generation sequencing, and ctDNA assays, are poised to refine response assessment and guide treatment duration.

5. Regulatory Considerations

The regulatory landscape for hematologic malignancy therapeutics will need to evolve to accommodate increasingly complex therapeutic approaches, including combination regimens and personalized medicine strategies [ 97 ]. Adaptive trial designs and master protocol approaches may help streamline the development and approval of novel combination therapies [ 98 , 99 ].

Real-world evidence generation will play an increasingly important role in supporting regulatory decisions and informing clinical practice [ 100 ]. Post-marketing studies will be essential for understanding long-term safety and efficacy of novel therapies in diverse patient populations [ 101 ].

International harmonization of regulatory standards and approval processes could help ensure more equitable global access to novel therapies while maintaining appropriate safety and efficacy standards [ 102 ].

6. Conclusions

The therapeutic revolution in hematologic malignancies marks a paradigm shift that has fundamentally redefined clinical practice and patient expectations. The decisive shift from generalized cytotoxic regimens to highly specific, targeted therapies and potent immunotherapies has unlocked unprecedented rates of deep, durable remission across a spectrum of blood cancers. While these advances offer immense promise, the path forward requires sustained focus on several critical areas. Specifically, future efforts must concentrate on optimizing next-generation combination regimens, comprehensively understanding and circumventing mechanisms of acquired drug resistance, and ensuring equitable access to these high-cost, life-extending treatments by addressing financial burden. Continued translational research into novel molecular targets and the adoption of dynamic, adaptive clinical trial designs will be crucial to further personalize therapy, refine treatment duration, and ultimately transition more hematologic cancers towards increased remission rates and disease-free survival.

Author Contributions

Conceptualization G.K.M., A.W.H. and M.R.S., Methodology, G.K.M., A.W.H. and M.R.S., Validation G.K.M., A.W.H. and M.R.S., formal analysis G.K.M., A.W.H. and M.R.S., resources G.K.M., A.W.H. and M.R.S., writing—original draft preparation G.K.M., A.W.H. and M.R.S., writing—review and editing G.K.M., A.W.H. and M.R.S., Visualization G.K.M., A.W.H. and M.R.S., Supervision G.K.M. and M.R.S., project administration G.K.M., A.W.H. and M.R.S. All authors have read and agreed to the published version of the manuscript.

Data Availability Statement

No new data were created or analyzed in this study.

Conflicts of Interest

The authors declare no conflicts of interest.

Funding Statement

This research received no external funding.

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

References

1. Kaye D., Isidori A. Current Challenges in Hematology: Awareness, Prevention, Equity. Front. Oncol. 2021;11:653020. doi: 10.3389/fonc.2021.653020.

2. Shahid K., Khalife M., Dabney R., Phan A.T. Immunotherapy and Targeted Therapy-the New Roadmap in Cancer Treatment. Ann. Transl. Med. 2019;7:595. doi: 10.21037/atm.2019.05.58.

3. Chabner B.A., Gehri J., Thompson B.B. Reinventing Chemotherapy. Oncologist. 2025;30:oyae331. doi: 10.1093/oncolo/oyae331.

4. Hirsh R., Moyers J., Benjamin D., Pourhassan H. Evaluating Recent Drug Approvals for Hematologic Malignancies Utilizing the New European Society of Medical Oncology Magnitude of Clinical Benefit Scale for Hematology (ESMO-MCBS:H) Blood. 2024;144:7638. doi: 10.1182/blood-2024-208782.

5. Elmacken M., Mahat U., Verdun N., Fashoyin-Aje L. Regulatory Considerations for Approval of Chimeric Antigen Receptor T Cell Therapies for Treatment of Hematological Malignancies. Blood. 2024;144:7765. doi: 10.1182/blood-2024-210267.

6. Lovell A.R., Jammal N., Bose P. Selecting the Optimal BTK Inhibitor Therapy in CLL: Rationale and Practical Considerations. Ther. Adv. Hematol. 2022;13:20406207221116577. doi: 10.1177/20406207221116577.

7. Forsberg M., Konopleva M. Therapy for Acute Myeloid Leukemia in Older and Unfit Adults. Haematologica. 2024;109:3832–3834. doi: 10.3324/haematol.2024.286233.

8. Bangolo A., Amoozgar B., Mansour C., Zhang L., Gill S., Ip A., Cho C. Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies. Cancers. 2025;17:282. doi: 10.3390/cancers17020282.

9. Abramson J.S., Solomon S.R., Arnason J., Johnston P.B., Glass B., Bachanova V., Ibrahimi S., Mielke S., Mutsaers P., Hernandez-Ilizaliturri F., et al. Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma: Primary Analysis of the Phase 3 TRANSFORM Study. Blood. 2023;141:1675–1684. doi: 10.1182/blood.2022018730.

10. Khan S.H., Choi Y., Veena M., Lee J.K., Shin D.S. Advances in CAR T Cell Therapy: Antigen Selection, Modifications, and Current Trials for Solid Tumors. Front. Immunol. 2024;15:1489827. doi: 10.3389/fimmu.2024.1489827.

11. Shams F., Sharif E., Abbasi-Kenarsari H., Hashemi N., Hosseini M.S., Heidari N., Noori E., Amini A.H., Bazrgar M., Rouhani M., et al. CRISPR/Cas9 Technology for Modifying Immune Checkpoint in CAR-T Cell Therapy for Hematopoietic Malignancies. Curr. Gene Ther. 2025;25:1–29. doi: 10.2174/0115665232357078250331180413.

12. Bobillo M.S.O., Kambhampati S., Lee D., Hunter B.D., Egini O., Patel K., Reagan P.M., Bernasconi D., Kim S., Santiago Parrilla C., et al. Real-World (RW) Outcomes of Lisocabtagene Maraleucel (Liso-Cel) as Second-Line (2L) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. Blood. 2024;144:470. doi: 10.1182/blood-2024-199723.

13. Caimi P.F., Pacheco Sanchez G., Sharma A., Otegbeye F., Ahmed N., Rojas P., Patel S., Kleinsorge Block S., Schiavone J., Zamborsky K., et al. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma. Front. Immunol. 2021;12:745320. doi: 10.3389/fimmu.2021.745320.

14. Tam C., Thompson P.A. BTK Inhibitors in CLL: Second-Generation Drugs and Beyond. Blood Adv. 2024;8:2300–2309. doi: 10.1182/bloodadvances.2023012221.

15. Eichhorst B., Lamanna N., O’Brien S., Tam C., Qiu L., Yang K., Wu K., Salmi T., Barnes G., Brown J. Zanubrutinib versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Impact on Health-related Quality of Life. Hematol. Oncol. 2023;41:463–464. doi: 10.1002/hon.3164_341.

16. Ahn I.E., Brown J.R. Targeting Bruton’s Tyrosine Kinase in CLL. Front. Immunol. 2021;12:687458. doi: 10.3389/fimmu.2021.687458.

17. Frustaci A.M., Deodato M., Zamprogna G., Cairoli R., Montillo M., Tedeschi A. Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities. Cancers. 2023;15:1504. doi: 10.3390/cancers15051504.

18. Scarfò L. Novel Therapies and Combinations in CLL Refractory to BTK Inhibitors and Venetoclax. Hematol. Am. Soc. Hematol. Educ. Program. 2022;2022:316–322. doi: 10.1182/hematology.2022000344.

19. Wang H., Zhou Q., Li L., Song W., Peng S., Chen X., Xu L., Sumiyoshi T., Jin W., Shen Z. Bgb-16673, a Selective BTK Degrader, Exhibits Deeper Inhibition of Cancer Cell Signaling Pathways and Better Efficacy in MCL Models. Blood. 2024;144:5833. doi: 10.1182/blood-2024-202909.

20. Short N.J., Daver N., Dinardo C.D., Kadia T., Nasr L.F., Macaron W., Yilmaz M., Borthakur G., Montalban-Bravo G., Garcia-Manero G., et al. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. J. Clin. Oncol. 2024;42:1499–1508. doi: 10.1200/JCO.23.01911.

21. Lachowiez C.A., Loghavi S., Zeng Z., Tanaka T., Kim Y.J., Uryu H., Turkalj S., Jakobsen N.A., Luskin M.R., Duose D.Y., et al. A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies. Blood Cancer Discov. 2023;4:276–293. doi: 10.1158/2643-3230.BCD-22-0205.

22. Wang L., Song J., Xiao X., Li D., Liu T., He X. Comparison of Venetoclax and Ivosidenib/Enasidenib for Unfit Newly Diagnosed Patients with Acute Myeloid Leukemia and IDH1/2 Mutation: A Network Meta-Analysis. J. Chemother. 2024;36:202–207. doi: 10.1080/1120009X.2023.2247200.

23. Shastri T., Trabolsi A., Arumov A., Schatz J.H. Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline. BioDrugs. 2025;39:793–814. doi: 10.1007/s40259-025-00735-z.

24. Tacchetti P., Barbato S., Mancuso K., Zamagni E., Cavo M. Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma. Cancers. 2024;16:2337. doi: 10.3390/cancers16132337.

25. Firestone R., Lesokhin A.M., Usmani S.Z. An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma. Blood Cancer Discov. 2023;4:433–436. doi: 10.1158/2643-3230.BCD-23-0176.

26. Razzo B.M., Midha S., Portuguese A.J., Grajales-Cruz A.F., De Menezes Silva Corraes A., Costello P., Liu Y., Sperling A.S., Nadeem O., Dima D., et al. Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium. Blood Cancer Discov. 2025;6:561–571. doi: 10.1158/2643-3230.BCD-24-0354.

27. Rees M., Abdallah N., Yohannan B., Gonsalves W.I. Bispecific Antibody Targets and Therapies in Multiple Myeloma. Front. Immunol. 2024;15:1424925. doi: 10.3389/fimmu.2024.1424925.

28. Verkleij C.P.M., O’Neill C.A., Broekmans M.E.C., Frerichs K.A., Bruins W.S.C., Duetz C., Kruyswijk S., Baglio S.R., Skerget S., Montes de Oca R., et al. T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple Myeloma. Clin. Cancer Res. 2024;30:3006–3022. doi: 10.1158/1078-0432.CCR-23-3333.

29. Waldschmidt J.M., Rasche L. BCMA Bispecifics: Breaking the Chains of Resistance. Blood. 2024;144:2566–2568. doi: 10.1182/blood.2024026932.

30. Candoni A., Coppola G. A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia. Hematol. Rep. 2024;16:244–254. doi: 10.3390/hematolrep16020024.

31. Issa G.C., Aldoss I., Thirman M.J., DiPersio J., Arellano M., Blachly J.S., Mannis G.N., Perl A., Dickens D.S., McMahon C.M., et al. Menin Inhibition with Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101) J. Clin. Oncol. 2025;43:75–84. doi: 10.1200/JCO.24.00826.

32. DiNardo K.W., LeBlanc T.W., Chen H. Novel Agents and Regimens in Acute Myeloid Leukemia: Latest Updates from 2022 ASH Annual Meeting. J. Hematol. Oncol. 2023;16:17. doi: 10.1186/s13045-023-01411-x.

33. Adriaanse F.R.S., Schneider P., Arentsen-Peters S.T.C.J.M., da Fonseca A.M.N., Stutterheim J., Pieters R., Zwaan C.M., Stam R.W. Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic and Myeloid Leukemia. Int. J. Mol. Sci. 2024;25:6020. doi: 10.3390/ijms25116020.

34. Jen W.-Y., Kantarjian H., Kadia T.M., DiNardo C.D., Issa G.C., Short N.J., Yilmaz M., Borthakur G., Ravandi F., Daver N.G. Combination Therapy with Novel Agents for Acute Myeloid Leukaemia: Insights into Treatment of a Heterogenous Disease. Br. J. Haematol. 2024;205:30–47. doi: 10.1111/bjh.19519.

35. Konopleva M., Thirman M.J., Pratz K.W., Garcia J.S., Recher C., Pullarkat V., Kantarjian H.M., DiNardo C.D., Dail M., Duan Y., et al. Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia. Clin. Cancer Res. 2022;28:2744–2752. doi: 10.1158/1078-0432.CCR-21-3405.

36. Stone R.M., Mandrekar S.J., Sanford B.L., Laumann K., Geyer S., Bloomfield C.D., Thiede C., Prior T.W., Döhner K., Marcucci G., et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N. Engl. J. Med. 2017;377:454–464. doi: 10.1056/NEJMoa1614359.

37. Perl A.E., Martinelli G., Cortes J.E., Neubauer A., Berman E., Paolini S., Montesinos P., Baer M.R., Larson R.A., Ustun C., et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N. Engl. J. Med. 2019;381:1728–1740. doi: 10.1056/NEJMoa1902688.

38. Cerchione C., Romano A., Daver N., DiNardo C., Jabbour E.J., Konopleva M., Ravandi-Kashani F., Kadia T., Martelli M.P., Isidori A., et al. IDH1/IDH2 Inhibition in Acute Myeloid Leukemia. Front. Oncol. 2021;11:639387. doi: 10.3389/fonc.2021.639387.

39. Stein E.M., DiNardo C.D., Fathi A.T., Mims A.S., Savona M.R., Stein A.S., Stone R.M., Winer E.S., Seet C.S., Döhner H., et al. Updated Survival and Response Analyses from a Phase 1 Study of Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation. Blood. 2021;138:1276. doi: 10.1182/blood-2021-146507.

40. Ramsey H.E., Fischer M.A., Lee T., Gorska A.E., Arrate M.P., Fuller L., Boyd K.L., Strickland S.A., Sensintaffar J., Hogdal L.J., et al. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. Cancer Discov. 2018;8:1566–1581. doi: 10.1158/2159-8290.CD-18-0140.

41. Condoluci A., Rossi D. Mechanisms of Resistance to Venetoclax. Blood. 2022;140:2094–2096. doi: 10.1182/blood.2022017341.

42. Worst B.C., van Tilburg C.M., Balasubramanian G.P., Fiesel P., Witt R., Freitag A., Boudalil M., Previti C., Wolf S., Schmidt S., et al. Next-generation personalised medicine for high-risk paediatric cancer patients—The INFORM pilot study. Eur. J. Cancer. 2016;65:91–101. doi: 10.1016/j.ejca.2016.06.009.

43. Massard C., Michiels S., Ferté C., Le Deley M.-C., Lacroix L., Hollebecque A., Verlingue L., Ileana E., Rosellini S., Ammari S., et al. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discov. 2017;7:586–595. doi: 10.1158/2159-8290.CD-16-1396.

44. Zhang J., Lu X., Li J., Miao Y. Combining BTK Inhibitors with BCL2 Inhibitors for Treating Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma. Biomark. Res. 2022;10:17. doi: 10.1186/s40364-022-00357-5.

45. Al-Sawaf O., Zhang C., Tandon M., Sinha A., Fink A.-M., Robrecht S., Samoylova O., Liberati A.M., Pinilla-Ibarz J., Opat S., et al. Venetoclax plus Obinutuzumab versus Chlorambucil plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia (CLL14): Follow-up Results from a Multicentre, Open-Label, Randomised, Phase 3 Trial. Lancet Oncol. 2020;21:1188–1200. doi: 10.1016/S1470-2045(20)30443-5.

46. Tam C.S., Allan J.N., Siddiqi T., Kipps T.J., Jacobs R., Opat S., Barr P.M., Tedeschi A., Trentin L., Bannerji R., et al. Fixed-Duration Ibrutinib plus Venetoclax for First-Line Treatment of CLL: Primary Analysis of the CAPTIVATE FD Cohort. Blood. 2022;139:3278–3289. doi: 10.1182/blood.2021014488.

47. Harttrampf A.C., Lacroix L., Deloger M., Deschamps F., Puget S., Auger N., Vielh P., Varlet P., Balogh Z., Abbou S., et al. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial. Clin. Cancer Res. 2017;23:6101–6112. doi: 10.1158/1078-0432.CCR-17-0381.

48. Maloney D.G., Grillo-López A.J., White C.A., Bodkin D., Schilder R.J., Neidhart J.A., Janakiraman N., Foon K.A., Liles T.M., Dallaire B.K., et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997;89:3059–3064.

49. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., Van Den Neste E., Salles G., Gaulard P., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002;346:235–242. doi: 10.1056/NEJMoa011795.

50. Roschewski M., Longo D.L., Wilson W.H. Chimeric Antigen Receptor T-Cell Therapy for Large B-Cell Lymphoma: Who, When, and How? N. Engl. J. Med. 2022;386:692–696. doi: 10.1056/NEJMe2118899.

51. Chen R., Wang F., Zhang H., Chen B. Brentuximab Vedotin for Treatment of Relapsed or Refractory Malignant Lymphoma: Results of a Systematic Review and Meta-Analysis of Prospective Studies. Drug Des. Devel Ther. 2015;9:2277–2283. doi: 10.2147/DDDT.S83592.

52. Sehn L.H., Hertzberg M., Opat S., Herrera A.F., Assouline S., Flowers C.R., Kim T.M., McMillan A., Ozcan M., Safar V., et al. Polatuzumab Vedotin plus Bendamustine and Rituximab in Relapsed/Refractory DLBCL: Survival Update and New Extension Cohort Data. Blood Adv. 2022;6:533–543. doi: 10.1182/bloodadvances.2021005794.

53. Chapuy B., Stewart C., Dunford A.J., Kim J., Kamburov A., Redd R.A., Lawrence M.S., Roemer M.G.M., Li A.J., Ziepert M., et al. Molecular Subtypes of Diffuse Large B Cell Lymphoma Are Associated with Distinct Pathogenic Mechanisms and Outcomes. Nat. Med. 2018;24:679–690. doi: 10.1038/s41591-018-0016-8.

54. Mouhieddine T.H., Costa B.A., Richter J. Advancements in Bispecific Antibodies for Multiple Myeloma: What’s New and What Lies Ahead. Semin. Hematol. 2025;62:58–70. doi: 10.1053/j.seminhematol.2024.12.001.

55. Tanenbaum B., Miett T., Patel S.A. The Emerging Therapeutic Landscape of Relapsed/Refractory Multiple Myeloma. Ann. Hematol. 2023;102:1–11. doi: 10.1007/s00277-022-05058-5.

56. Zhao J., Ren Q., Liu X., Guo X., Song Y. Bispecific Antibodies Targeting BCMA, GPRC5D, and FcRH5 for Multiple Myeloma Therapy: Latest Updates from ASCO 2023 Annual Meeting. J. Hematol. Oncol. 2023;16:92. doi: 10.1186/s13045-023-01489-3.

57. Mailankody S., Devlin S.M., Landa J., Nath K., Diamonte C., Carstens E.J., Russo D., Auclair R., Fitzgerald L., Cadzin B., et al. GPRC5D-Targeted CAR T Cells for Myeloma. N. Engl. J. Med. 2022;387:1196–1206. doi: 10.1056/NEJMoa2209900.

58. Kantarjian H., Stein A., Gökbuget N., Fielding A.K., Schuh A.C., Ribera J.M., Wei A., Dombret H., Foà R., Bassan R., et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N. Engl. J. Med. 2017;376:836–847. doi: 10.1056/NEJMoa1609783.

59. Kantarjian H.M., DeAngelo D.J., Stelljes M., Martinelli G., Liedtke M., Stock W., Gökbuget N., O’Brien S., Wang K., Wang T., et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N. Engl. J. Med. 2016;375:740–753. doi: 10.1056/NEJMoa1509277.

60. Vora A., Goulden N., Mitchell C., Hancock J., Hough R., Rowntree C., Moorman A.V., Wade R. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): A randomised controlled phase 3 trial. Lancet Oncol. 2014;15:809–818. doi: 10.1016/S1470-2045(14)70243-8.

61. Jiang V., Lee W., Zhang T., Jordan A., Yan F., Cai Q., McIntosh J., Vargas J., Liu Y., Wang M. The CDK9 Inhibitor Enitociclib Overcomes Resistance to BTK Inhibition and CAR-T Therapy in Mantle Cell Lymphoma. Biomark. Res. 2024;12:62. doi: 10.1186/s40364-024-00589-7.

62. Stephens D.M., Byrd J.C. Resistance to Bruton Tyrosine Kinase Inhibitors: The Achilles Heel of Their Success Story in Lymphoid Malignancies. Blood. 2021;138:1099–1109. doi: 10.1182/blood.2020006783.

63. Wang E., Mi X., Thompson M.C., Montoya S., Notti R.Q., Afaghani J., Durham B.H., Penson A., Witkowski M.T., Lu S.X., et al. Mechanisms of Resistance to Noncovalent Bruton’s Tyrosine Kinase Inhibitors. N. Engl. J. Med. 2022;386:735–743. doi: 10.1056/NEJMoa2114110.

64. Shah N.N., Fry T.J. Mechanisms of Resistance to CAR T Cell Therapy. Nat. Rev. Clin. Oncol. 2019;16:372–385. doi: 10.1038/s41571-019-0184-6.

65. Legato L., Bisio M., Fasano F., Benevolo Savelli C., Secreto C., Dellacasa C.M., Botto B., Busca A., Cerrano M., Freilone R., et al. Mechanisms of Resistance to CAR T-Cells and How to Overcome Them. Methods Protoc. 2025;8:108. doi: 10.3390/mps8050108.

66. El Achi H., Kanagal-Shamanna R. Biomarkers in Acute Myeloid Leukemia: Leveraging Next Generation Sequencing Data for Optimal Therapeutic Strategies. Front. Oncol. 2021;11:748250. doi: 10.3389/fonc.2021.748250.

67. Dekker S.E., Rea D., Cayuela J.-M., Arnhardt I., Leonard J., Heuser M. Using Measurable Residual Disease to Optimize Management of AML, ALL, and Chronic Myeloid Leukemia. Am. Soc. Clin. Oncol. Educ. Book. 2023;43:e390010. doi: 10.1200/EDBK_390010.

68. Stepan L., Ansari S., Okal A., Dell’Aringa J., Thompson E.G., Crotta A., Chow V.A., Abramson J.S., Kamdar M., Solomon S.R., et al. Circulating Tumor DNA (ctDNA) as an Early Outcome Predictor in Patients (Pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (Liso-Cel) Versus Standard of Care (SOC) Treatment (Tx) from the Phase 3, Randomized Transform Study. Blood. 2024;144:72. doi: 10.1182/blood-2024-199813.

69. Tettero J.M., Buisman Y., Ngai L.L., Bachas C., Gjertsen B.T., Kelder A., van de Loosdrecht A.A., Manz M.G., Pabst T., Scholten W., et al. Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML. Hemasphere. 2023;7:e981. doi: 10.1097/HS9.0000000000000981.

70. Jóna Á., Illés Á. Sequencing Cellular Therapies in the Management of Follicular Lymphoma. Cells. 2025;14:1671. doi: 10.3390/cells14211671.

71. Odetola O., Ma S. Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Curr. Hematol. Malig. Rep. 2023;18:130–143. doi: 10.1007/s11899-023-00700-z.

72. Awan F.T., Addison D., Alfraih F., Baratta S.J., Campos R.N., Cugliari M.S., Goh Y.T., Ionin V.A., Mundnich S., Sverdlov A.L., et al. International Consensus Statement on the Management of Cardiovascular Risk of Bruton’s Tyrosine Kinase Inhibitors in CLL. Blood Adv. 2022;6:5516–5525. doi: 10.1182/bloodadvances.2022007938.

73. Mela E., Frountzas M. Gastrointestinal Cancer: Outcomes and Therapeutic Management. J. Clin. Med. 2025;14:7541. doi: 10.3390/jcm14217541.

74. Kamau B., Shulimovich M., Samridhi S. The Impact of Novel Therapies on Quality-of-Life in Triple-Negative Breast Cancer: A Systematic Review of Clinical Trials. Cancers. 2025;17:3307. doi: 10.3390/cancers17203307.

75. Borate U., Huang Y., Welkie R.L., Swords R.T., Traer E., Stein E.M., Lin T.L., Madanat Y.F., Patel P.A., Collins R.H., et al. Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age. Blood. 2024;144:4324. doi: 10.1182/blood-2024-211178.

76. Tyner J.W. Integrating Functional Genomics to Accelerate Mechanistic Personalized Medicine. Cold Spring Harb. Mol. Case Stud. 2017;3:a001370. doi: 10.1101/mcs.a001370.

77. Cai Z., Poulos R.C., Liu J., Zhong Q. Machine Learning for Multi-Omics Data Integration in Cancer. iScience. 2022;25:103798. doi: 10.1016/j.isci.2022.103798.

78. Pauli C., De Boni L., Pauwels J.E., Chen Y., Planas-Paz L., Shaw R., Emerling B.M., Grandori C., Hopkins B.D., Rubin M.A. A Functional Precision Oncology Approach to Identify Treatment Strategies for Myxofibrosarcoma Patients. Mol. Cancer Res. 2022;20:244–252. doi: 10.1158/1541-7786.MCR-21-0255.

79. Das C., Adhikari S., Bhattacharya A., Chakraborty S., Mondal P., Yadav S.S., Adhikary S., Hunt C.R., Yadav K.K., Pandita S., et al. Epigenetic-Metabolic Interplay in the DNA Damage Response and Therapeutic Resistance of Breast Cancer. Cancer Res. 2023;83:657–666. doi: 10.1158/0008-5472.CAN-22-3015.

80. Jiang V.C., Liu Y., Lian J., Huang S., Jordan A., Cai Q., Lin R., Yan F., McIntosh J., Li Y., et al. Cotargeting of BTK and MALT1 Overcomes Resistance to BTK Inhibitors in Mantle Cell Lymphoma. J. Clin. Investig. 2023;133:e165694. doi: 10.1172/JCI165694.

81. Zhang M., Lam K.-P., Xu S. Natural Killer Cell Engagers (NKCEs): A New Frontier in Cancer Immunotherapy. Front. Immunol. 2023;14:1207276. doi: 10.3389/fimmu.2023.1207276.

82. In H., Park M., Lee H., Han K.H. Immune Cell Engagers: Advancing Precision Immunotherapy for Cancer Treatment. Antibodies. 2025;14:16. doi: 10.3390/antib14010016.

83. Salas-Mckee J., Kong W., Gladney W.L., Jadlowsky J.K., Plesa G., Davis M.M., Fraietta J.A. CRISPR/Cas9-Based Genome Editing in the Era of CAR T Cell Immunotherapy. Hum. Vaccin. Immunother. 2019;15:1126–1132. doi: 10.1080/21645515.2019.1571893.

84. Elmas E., Saljoughian N., de Souza Fernandes Pereira M., Tullius B.P., Sorathia K., Nakkula R.J., Lee D.A., Naeimi Kararoudi M. CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy. Front. Oncol. 2022;12:834002. doi: 10.3389/fonc.2022.834002.

85. Hu C., Lai W., Tian B., Xu X., Xie S., Zhong W., Kang H., Chen X., Li H., Xu J., et al. Application and Prospects of Genetic Engineering in CAR-NK Cell Therapy. Front. Immunol. 2025;16:1600411. doi: 10.3389/fimmu.2025.1600411.

86. Weeks C., Shoukier M., Dalgetty M., Vuppala R., Desai S., Simon A.B., Kota V.K., Bryan L.J., Cortes J.E. Financial Toxicity of FDA-Approved Hematologic Malignancy Drugs: An Epidemiological Analysis of Cost. Blood. 2024;144:7578. doi: 10.1182/blood-2024-206129.

87. Abdo L., Batista-Silva L.R., Bonamino M.H. Cost-Effective Strategies for CAR-T Cell Therapy Manufacturing. Mol. Ther. Oncol. 2025;33:200980. doi: 10.1016/j.omton.2025.200980.

88. Tu S.S., Goode R., Turner M., Van de Wiele V. Accelerating Biosimilar Market Access: The Case for Allowing Earlier Standing. J. Law. Biosci. 2025;12:lsae030. doi: 10.1093/jlb/lsae030.

89. Neumann P.J., Chambers J.D., Simon F., Meckley L.M. Risk-Sharing Arrangements That Link Payment for Drugs to Health Outcomes Are Proving Hard to Implement. Health Aff. 2011;30:2329–2337. doi: 10.1377/hlthaff.2010.1147.

90. McCune J.M., Stevenson S.C., Doehle B.P., Trenor C.C., 3rd, Turner E.H., Spector J.M. Collaborative Science to Advance Gene Therapies in Resource-Limited Parts of the World. Mol. Ther. 2021;29:3101–3102. doi: 10.1016/j.ymthe.2021.05.024.

91. Huskins W.C., Fowler V.G.J., Evans S. Adaptive Designs for Clinical Trials: Application to Healthcare Epidemiology Research. Clin. Infect. Dis. 2018;66:1140–1146. doi: 10.1093/cid/cix907.

92. Verdaguer H., Saurí T., Macarulla T. Predictive and Prognostic Biomarkers in Personalized Gastrointestinal Cancer Treatment. J. Gastrointest. Oncol. 2017;8:405–417. doi: 10.21037/jgo.2016.11.15.

93. Mason-Osann E., Pomeroy A.E., Palmer A.C., Mettetal J.T. Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid Leukemia. Blood Cancer Discov. 2024;5:95–105. doi: 10.1158/2643-3230.BCD-23-0067.

94. Siddiqui A., Purwar A., Purwar R., Kumar S. Next-Generation CAR-T: In Vivo Engineering with Lipid Nanoparticles. J. Clin. Med. Surg. 2025;5:1208.

95. Hurtado L., Gonzalez Concepcion M., Flix-Valle A., Ruiz-Romeo M., Gonzalez-Rodriguez S., Peña M., Paviglianiti A., Pera Jambrina M.A., Sureda A., Ochoa-Arnedo C., et al. Telemedicine with Wearable Technologies in Patients Undergoing Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy (TEL-HEMATO Study): Prospective Noninterventional Single-Center Study. JMIR Form. Res. 2024;8:e55918. doi: 10.2196/55918.

96. Foser S., Maiese K., Digumarthy S.R., Puig-Butille J.A., Rebhan C. Looking to the Future of Early Detection in Cancer: Liquid Biopsies, Imaging, and Artificial Intelligence. Clin. Chem. 2024;70:27–32. doi: 10.1093/clinchem/hvad196.

97. Reis M.E., Bettencourt A., Ribeiro H.M. The Regulatory Challenges of Innovative Customized Combination Products. Front. Med. 2022;9:821094. doi: 10.3389/fmed.2022.821094.

98. Zang Y., Lee J.J. Adaptive Clinical Trial Designs in Oncology. Chin. Clin. Oncol. 2014;3:49. doi: 10.3978/j.issn.2304-3865.2014.06.04.

99. Confeld M. Master Protocols in Oncology: Opportunities, Challenges, and Strategic Approaches to Design and Implementation. J. Clin. Oncol. 2025;43:e23010. doi: 10.1200/JCO.2025.43.16_suppl.e23010.

100. Hennessy S., Atsuta Y., Hill S., Rägo L., Juhaeri J. Real-World Data and Real-World Evidence in Regulatory Decision Making: Report Summary from the Council for International Organizations of Medical Sciences (CIOMS) Working Group XIII. Pharmacoepidemiol. Drug Saf. 2025;34:e70117. doi: 10.1002/pds.70117.

101. Schick A., Miller K.L., Lanthier M., Dal Pan G., Nardinelli C. Evaluation of Pre-Marketing Factors to Predict Post-Marketing Boxed Warnings and Safety Withdrawals. Drug Saf. 2017;40:497–503. doi: 10.1007/s40264-017-0526-1.

102. Rajpuriya D. Regulatory Harmonization: Streamlining Global Pharmaceutical Validation Practices. Int. J. Sci. Res. Comput. Sci. Eng. Inf. Technol. 2025;11:1173–1183. doi: 10.32628/CSEIT251112118.

Associated Data

Data Availability Statement

No new data were created or analyzed in this study.